DAX24.160 -0,6%ESt505.334 -0,4%Top 10 Crypto15,64 -0,3%Dow44.694 ±0,0%Nas21.093 +0,2%Bitcoin99.030 -1,6%Euro1,1725 -0,2%Öl69,06 -0,4%Gold3.343 -0,8%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Volkswagen (VW) vz. 766403 Deutsche Bank 514000 NVIDIA 918422 Tesla A1CX3T PUMA 696960 RENK RENK73 Infineon 623100 Deutsche Telekom 555750 Bayer BAY001 Lufthansa 823212 Mercedes-Benz Group (ex Daimler) 710000 SAP 716460 BASF BASF11 DroneShield A2DMAA
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Zoll-Konflikt: DAX tiefer -- Wall Street höher -- Intel macht weniger Gewinn -- VW senkt Prognose erneut -- Rheinmetall & Co., Droneshield, Novo Nordisk, Palantir, Newmont im Fokus
Top News
US-Börsen zeigen sich im Freitagshandel uneins: Zollstreit und Rekorde weiter im Fokus US-Börsen zeigen sich im Freitagshandel uneins: Zollstreit und Rekorde weiter im Fokus
Handelsstreit mit den USA: Blick auf 1. August als Zoll-Ultimatum-Datum - DAX gibt nach Handelsstreit mit den USA: Blick auf 1. August als Zoll-Ultimatum-Datum - DAX gibt nach
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Ãœbersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Wie Urlaubsgeld. Nur jeden Monat. Plan12. Jetzt mehr erfahren!

Kodiak Sciences Aktie

Handeln
Aktien-Sparplan anlegen
6,89 EUR +1,27 EUR +22,62 %
FSE
8,23 USD -0,02 USD -0,24 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.370,34 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2N6P0

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS50015M1099

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolKOD

Kodiak Sciences Aktien News

DatumMeistgelesen
PR NewswireKodiak Sciences to Host Investor R&D Day on July 16, 2025
PR NewswireKodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society
PR NewswireKodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference
Wer­bungKodiak Sciences-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireKodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results
PR NewswireKodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases
PR NewswireKodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
PR NewswireKodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy
PR NewswireKodiak Sciences to Present at Glaucoma 360 New Horizons Forum 2025
PR NewswireKodiak Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
PR NewswireKodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results
PR NewswireKodiak Sciences to Participate in Upcoming Investor Conferences
PR NewswireKodiak Sciences to Present at Innovate Retina 2024
PR NewswireKodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time
PR NewswireKodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City
PR NewswireKodiak Sciences Announces Recent Business Highlights and Second Quarter 2024 Financial Results
PR NewswireKodiak Sciences to Present at Upcoming Investor and Clinical Conferences
PR NewswireKodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results
PR NewswireKodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy
PR NewswireKodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Co...
PR NewswireKodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
PR NewswireKodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024
PR NewswireKodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting
PR NewswireKodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PR NewswireKodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference
PR NewswireKodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights
PR NewswireKodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regul...
PR NewswireKODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY AN...
PR NewswireKodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society
PR NewswireKodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
PR NewswireNew one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vei...
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD
PR NewswireKodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Kodiak Sciences Inc. - KOD
PR NewswireKodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocim...
PR NewswireKodiak Sciences to Present at Upcoming Investor Conferences
PR NewswireKodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights
PR NewswireKodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting
PR NewswireKodiak Sciences Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases

Kodiak Sciences News

Kodiak Sciences News: auf dieser Seite finden Sie alle Kodiak Sciences News und Nachrichten zur Kodiak Sciences Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Kodiak Sciences News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Kodiak Sciences News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.